Related Experiment Video

Updated: Nov 9, 2025

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes
10:17

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes

Published on: April 26, 2019

7.2K

Metabolic complications of hepatitis C virus infection

Rahul Chaudhari1, Sherouk Fouda2, Ashik Sainu3

  • 1Department of Medicine, Pennsylvania Hospital of the University of Pennsylvania, Pennsylvania, PA 19104, United States.

World Journal of Gastroenterology
|April 9, 2021
PubMed

Insights

Hepatitis C virus (HCV) infection impacts multiple organs, causing metabolic disturbances and increasing risks for cardiovascular disease and liver cancer. Understanding these connections is vital for managing HCV

Area of Science:

  • Hepatology
  • Virology
  • Metabolic Medicine

Background:

  • Hepatitis C virus (HCV) infection is a systemic disease affecting multiple organs beyond the liver.
  • HCV is linked to extrahepatic disorders like atherosclerosis, metabolic disturbances, and lymphoproliferative diseases.
  • The interplay between HCV, metabolic syndrome, and cardiovascular disease poses a significant global health challenge.

Purpose of the Study:

  • To review current knowledge on the metabolic manifestations of Hepatitis C virus infection.
  • To explore the pathways through which metabolic changes influence the natural history of HCV.
  • To highlight the significance of cellular and molecular mechanisms in HCV-related organ dysfunction.

Main Methods:

  • Comprehensive literature review of existing studies on Hepatitis C virus and metabolic disorders.
  • Analysis of cellular and molecular mechanisms governing organ interplay in HCV infection.
  • Synthesis of data on the impact of metabolic changes on HCV chronicity and virulence.

Main Results:

  • HCV infection is associated with diverse extrahepatic manifestations, including metabolic and cardiovascular disorders.
  • Metabolic disorders, such as obesity and metabolic syndrome, exacerbate liver disease progression, including fibrosis and hepatocellular carcinoma.
  • The liver-muscle-adipose axis is significantly affected by HCV, contributing to systemic health burdens.

Conclusions:

  • Metabolic manifestations are integral to Hepatitis C virus infection, influencing its systemic impact.
  • Addressing metabolic disturbances is crucial for managing HCV and its associated complications.
  • Further research into the molecular interplay between HCV and metabolic pathways is warranted.

Keywords:
Cardiovascular diseasesChronic hepatitis C infectionDiabetes mellitusFatty liverInsulin resistanceMetabolic syndrome

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.6K
Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis05:56

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

273

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
67
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
50
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.5K
Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
259
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
65
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
213